Skip to content

Investors
Press Releases
About Us
Contact

Science
Sepranolone
Tourette Syndrome
OCD
PMDD

Science
Sepranolone
Tourette Syndrome
OCD
PMDD

Investors
Press Releases
About Us
Contact

OMNI EKONOMI

2019-06-122019-12-01

Asarina Pharma: DNB höjer riktkursen till 44 KR (37) (DNB increases target share value to 44 SEK)

Swedish investor site on increased valuation of Asarina Pharma.

Asarina Pharma AB
Registered office in Solna, Sweden
Reg no 556698-0750
© All rights reserved

Neve | Powered by WordPress

Contact

Asarina Pharma AB
Karolinska Institutet Science Park
Fogdevreten 2
SE – 171 65 Solna, Sweden

Navigation

Home
Science
Sepranolone
Menstrual Migraine
Tourette Syndrome
PMDD
Investors
Press Releases
About Us
Contact

About Asarina Pharma

Asarina Pharma is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion, menstrual and neurological disorders. Our product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

Asarina Pharma AB
Registered office in Solna, Sweden
Reg no 556698-0750
© All rights reserved

Neve | Powered by WordPress

Contact

Asarina Pharma AB
Karolinska Institutet Science Park
Fogdevreten 2
SE – 171 65 Solna, Sweden

Navigation

Home
Science
Sepranolone
Menstrual Migraine
Tourette Syndrome
PMDD
Investors
Press Releases
About Us
Contact

About Asarina Pharma

Asarina Pharma is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion, menstrual and neurological disorders. Our product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.